Clinical study on the effect of Takra Dhara and Nayanasukha varthi anjana karma in the management of Timira wsr to Non Proliferative Diabetic Retinopathy
- Conditions
- Health Condition 1: H350- Background retinopathy and retinalvascular changesHealth Condition 2: H350- Background retinopathy and retinalvascular changes
- Registration Number
- CTRI/2023/12/060544
- Lead Sponsor
- Parul University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients with a history of 10 years or more duration of type 2 diabetes Mellitus are taken for the study with oral hypoglycemic drugs or insulin.
2. Patients with symptoms like blurred vision, fluctuating vision, gradual vision loss, cloudy or hazy vision, and flashes of lights are included.
3. Patients with fundus changes as seen through the direct ophthalmoscope after dilating the eye like small dot and blot hemorrhages, multiple cotton wool spots, vascular changes such as venous beading, attenuation of the arterioles, venous loop, dilatation of veins are included.
1. Patients with proliferative diabetic retinopathy, high-risk diabetic retinopathy, advanced diabetic eye diseases, other vascular retinopathies like hypertensive retinopathy, retinopathy of blood dyscrasias, gestational diabetic retinopathy, retinopathy of prematurity, sickle cell retinopathy are excluded.
2. patients with other systemic disorders like renal diseases, chronic hyperglycemia, hyper lipidemia, and cardiovascular diseases are excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Combined effect of takra dhara shirodhara and nayanasukha varthi as anjana karma is effective for the management of early to moderate stages of non proliferative diabetic retinopathyTimepoint: 2 months
- Secondary Outcome Measures
Name Time Method Combined effect of takradhara & nayanasukha varthi anjana with contemporary anti-glycemic drugs in the early to moderate stage of non proliferative diabetic retinopathyTimepoint: 2 months